The 12th annual New York GU: Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies will focus on essential clinical topics in disease management.
The meeting, hosted by Physicians’ Education Resource, a top resource for continuing medical education, will be March 15-16 in New York.
It will be co-chaired by Daniel P. Petrylak, MD, professor of medicine and urology, co-director of the Signal Transduction Research Program, Yale Cancer Center, and Leonard G. Gomella, MD, the Bernard W. Godwin Jr. professor of prostate cancer, and chairman, department of urology, at Philadelphia’s Jefferson Medical College.
“This educational activity will outline the use of patient- and disease-specific characteristics to inform clinical decision making in the management of patients with genitourinary (GU) malignancies, along with discussing current strategies and practice-changing evidence for the management of patients across multiple lines of care through many interactive sessions,” Phil Talamo, Physicians’ Education Resource president, said in a news release.
Attendees will discuss optimal use of chemotherapeutic approaches, local treatments, androgen-deprivation therapies, immunotherapies and targeted treatments. They will also discuss the use of radiopharmaceuticals, the application of prognostic biomarkers, and approaches that might mitigate predictable treatment-related adverse effects.
Clinicians will also explore promising new and emerging data, such as combining and sequencing treatments across the disease continuum. They will also discuss important clinical trial data on, for example, prostate-specific antigen (PSA) screening and decisions regarding treatment of castration-sensitive prostate cancer, a cancer whose treatment landscape has rapidly evolved over the past few years.
The event is targeted to oncologists involved in the treatment of patients with cancers in the urinary system and the male reproductive system, collectively known as genitourinary malignancies.
Also welcome are urologists, fellows, nurses and nurse practitioners, pharmacists, physician assistants, nuclear medicine physicians, researchers, and other healthcare professionals interested in the treatment of these cancers.
After the meeting, participants should be able to:
- Outline the use of patient- and disease-specific characteristics to inform clinical decision making in patient management;
- Discuss current strategies and practice-changing evidence for patient management across multiple lines of care;
- Explain how to proactively mitigate expected treatment-related toxicities associated with immunotherapeutic and targeted treatment approaches;
- Apply emerging clinical trial data for disease management in the context of changing treatment paradigms.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?